Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder

Expert Review of Neurotherapeutics

Volumn 10, Issue 11, 2010, Pages 1637-1658

  Bobo, William V ^a   Shelton, Richard C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bipolar disorder; bipolar maintenance; depot risperidone; maintenance treatment; relapse; risperidone long acting injectable

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FLUPHENAZINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PROPRANOLOL; QUETIAPINE; RELPREVV; RISPERIDONE; SUSTENNA; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

AGE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GALACTORRHEA; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HOSPITALIZATION; HUMAN; INSOMNIA; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MENSTRUAL IRREGULARITY; MUSCLE RIGIDITY; PROLACTIN BLOOD LEVEL; QT INTERVAL; RELAPSE; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; TARDIVE DYSKINESIA; TREMOR; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; RISPERIDONE;

EID: 78049481589     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.143     Document Type: Review

References (169)

1. Rihmer Z, Angst J. Mood Disorders: Epidemiology. Sadock BJ, Sadock VA, Ruiz P (Eds). Lippincott Williams & Wilkins, PA, USA, 1645-1652 (2009).
2. Bauer M, Pfennig A. Epidemiology of bipolar disorders. Epilepsia 46(Suppl. 4), 8-13 (2005).
3. Angst J, Gamma A, Lewinsohn P. The evolving epidemiology of bipolar disorder. World Psychiatry 1, 146-148 (2002).
4. Kessler RC, Chiu W T, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617-627 (2005).
5. Hirschfeld RM, Calabrese JR, Weissman MM et al. Screening for bipolar disorder in the community. J. Clin. Psychiatry 64, 53-59 (2003).
6. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59, 530-537 (2002).
7. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry 60, 261-269 (2003).
8. Geller B, Tillman R, Craney JL, Bolhofner K. Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. Arch. Gen. Psychiatry 61, 459-467 (2004).
9. Birmaher B, Axelson D, Strober M et al. Clinical course of children and adolescents with bipolar spectrum disorders. Arch. Gen. Psychiatry 63, 175-183 (2006).
10. Swann AC. Long-term treatment in bipolar disorder. J. Clin. Psychiatry 66(Suppl. 1), 7-12 (2005).
11. Suppes T, Dennehy EB, Hirschfeld RM et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry 66, 870-886 (2005).
12. Keck PE, Perlis RH, Otto MW, Carpenter D, Ross R, Docherty JP. The Expert Consensus Guideline Series: Treatment of Bipolar Disorder 2004. Postgraduate Medicine Special Report, 1-120 (2004).
13. Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 11, 225-255 (2009).
14. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (Revision). Am. J. Psychiatry 159, 1-50 (2002).
15. Tohen M, Zarate CA Jr, Hennen J et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and frst recurrence. Am. J. Psychiatry 160, 2099-2107 (2003).
16. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am. J. Psychiatry 152, 1635-1640 (1995).
17. Coryell W, Turvey C, Endicott J et al. Bipolar I affective disorder: predictors of outcome after 15 years. J. Affect. Disord. 50, 109-116 (1998).
18. Goldberg JF, Harrow M. Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up. J. Affect. Disord. 81, 123-131 (2004).
19. Chengappa KN, Hennen J, Baldessarini RJ et al. Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disord. 7, 68-76 (2005).
20. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr. Scand. 105, 164-172 (2002).
21. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J. Clin. Psychiatry 63, 384-390 (2002).
22. Rosa AR, Marco M, Fachel JM, Kapczinski F, Stein AT, Barros HM. Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 217-224 (2007).
23. Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am. J. Psychiatry 159, 1927-1929 (2002).
24. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am. J. Psychiatry 153, 993-1000 (1996).
25. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch. Gen. Psychiatry 48, 1082-1088 (1991).
26. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr. Serv. 52, 805-811 (2001).
27. Lew KH, Chang EY, Rajagopalan K, Knoth RL. The effect of medication adherence on health care utilization in bipolar disorder. Manag. Care Interface 19, 41-46 (2006).
28. Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 21, 441-448 (2007).
29. McEvoy JP. Risks versus benefts of different types of long-acting injectable antipsychotics. J. Clin. Psychiatry 67(Suppl. 5), 15-18 (2006).
30. Dencker SJ, Axelsson R. Optimising the use of depot antipsychotics. CNS Drugs 6, 367-381 (1996).
31. Manji HK, Lenox RH. The nature of bipolar disorder. J. Clin. Psychiatry 61(Suppl. 13), 42-57 (2000).
32. Martinowich K, Schloesser RJ, Manji HK. Bipolar disorder: from genes to behavior pathways. J. Clin. Invest. 119, 726-736 (2009).
33. Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA Jr. The neurobiology of the switch process in bipolar disorder: a review. J. Clin. Psychiatry DOI: 10.4088/JCP.09r05259gre (2010) (Epub ahead of print).
34. Craig TJ, Grossman S, Mojtabai R et al. Medication use patterns and 2-year outcome in frst-admission bipolar disorder with psychotic features. Bipolar Disord. 6, 406-415 (2004).
35. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr. Serv. 59, 1175-1183 (2008).
36. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 5, 421-433 (2003).
37. Grunze HC. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? CNS Spectr. 13, 790-795 (2008).
38. Post RM, Leverich GS, Nolen WA et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord. 5, 396-406 (2003).
39. Sachs GS, Nierenberg AA, Calabrese JR et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med. 356, 1711-1722 (2007).
40. Bowden CL, Brugger AM, Swann AC et al. Effcacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 271, 918-924 (1994).
41. Bowden CL, Grunze H, Mullen J et al. A randomized, double-blind, placebo-controlled effcacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry 66, 111-121 (2005).
42. Goldberg JF, Garno JL, Harrow M. Long-term remission and recovery in bipolar disorder: a review. Curr. Psychiatry Rep. 7, 456-461 (2005).
43. Ghaemi SN, Hsu DJ, Thase ME et al. Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. Psychiatr. Serv. 57, 660-665 (2006).
44. Ketter TA, Wang PW, Nowakowska C, Marsh WK, Bonner J. Treatment of acute mania in bipolar disorder. In: Advances in Treatment of Bipolar Disorder. Ketter TA (Ed.). American Psychiatric Publishing, Washington, DC, USA, 11-55 (2005).
45. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br. J. Psychiatry 182, 141-147 (2003).
46. Tohen M, Bowden CL, Smulevich AB et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br. J. Psychiatry 192, 135-143 (2008).
47. Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J. Clin. Psychopharmacol. 24, 599-606 (2004).
48. Vieta E, T'joen C, McQuade RD et al. Effcacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am. J. Psychiatry 165, 1316-1325 (2008).
49. Prien RF, Caffey EM Jr, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch. Gen. Psychiatry 26, 146-153 (1972).
50. Shopsin B, Gershon S, Thompson H, Collins P. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch. Gen. Psychiatry 32, 34-42 (1975).
51. Cookson J, Silverstone T, Wells B. Double-blind comparative clinical trial of pimozide and chlorpromazine in mania. A test of the dopamine hypothesis. Acta Psychiatr. Scand. 64, 381-397 (1981).
52. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin. Neuropharmacol. 21, 176-180 (1998).
53. McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J. Clin. Psychiatry 57, 142-146 (1996).
54. Chou JC, Czobor P, Charles O et al. Acute mania: haloperidol dose and augmentation with lithium or lorazepam. J. Clin. Psychopharmacol. 19, 500-505 (1999).
55. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch. Gen. Psychiatry 60, 1218-1226 (2003).
56. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur. Neuropsychopharmacol. 15, 573-585 (2005).
57. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br. J. Psychiatry 52(Suppl.), S13-S19 (2009).
58. Ahlfors UG, Baastrup PC, Dencker SJ et al. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr. Scand. 64, 226-237 (1981).
59. Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AH, Hopwood SE. Comparison of the prophylactic action of fupenthixol with placebo in lithium treated manic-depressive patients. Br. J. Psychiatry 148, 723-725 (1986).
60. Bond DJ, Pratoomsri W, Yatham LN. Depot antipsychotic medications in bipolar disorder: a review of the literature. Acta Psychiatr. Scand. (Suppl. 434), 3-16 (2007).
61. White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int. Clin. Psychopharmacol. 8, 119-122 (1993).
62. Cavazzoni PA, Berg PH, Kryzhanovskaya LA et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J. Clin. Psychiatry 67, 107-113 (2006).
63. Keck PE Jr, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J. Clin. Psychiatry 61(Suppl. 4), 33-38 (2000).
64. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J. Clin. Psychopharmacol. 28, 203-209 (2008).
65. Malhotra AK, Litman RE, Pickar D. Adverse effects of antipsychotic drugs. Drug Saf. 9, 429-436 (1993).
66. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 161, 414-425 (2004).
67. Davis JM, Chen N, Glick ID. A meta-analysis of the effcacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60, 553-564 (2003).
68. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf. 22, 195-214 (2000).
69. Package insert. Risperdal Consta (risperidone) long-acting injection: US prescribing information. Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Titusville, NJ, USA (2010).
70. Gefvert O, Eriksson B, Persson P et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int. J. Neuropsychopharmacol. 8, 27-36 (2005).
71. Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann. Pharmacother. 38, 2122-2127 (2004).
72. van Rossum JM. The signifcance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch.Int. Pharmacodyn. Ther. 160, 492-494 (1966).
73. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 1217-1219 (1975).
74. Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull. 2, 19-76 (1976).
75. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. 7(Suppl. 1), S1-S5 (2004).
76. Bobo W V, Rapoport J, Abi-Dargham A, Meltzer HY. The neurobiology of schizophrenia. In: Psychiatry. Third Edition. Tasman A, Maj M, First MB, Kay J, Lieberman JA (Eds). John Wiley & Sons Inc, NH, USA, 301-316 (2008).
77. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 68, 29-39 (2000).
78. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry 60(Suppl. 10), 5-14 (1999).
79. Cosi C, Carilla-Durand E, Assie MB et al. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur. J. Pharmacol. 535, 135-144 (2006).
80. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affnity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302, 381-389 (2002).
81. Meltzer HY, Matsubara S, Lee JC. Classifcation of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238-246 (1989).
82. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affnities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 25, 390-392 (1989).
83. Schotte A, Janssen PF, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 124, 57-73 (1996).
84. Eerdekens M, Van Hore I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr. Res. 70, 91-100 (2004).
85. Ramstack M, Grandolf GP, Mannaert E, D'Hoore P, Lasser RA. Long-acting risperidone: prolonged-release injectable delivery of risperidone using Medisorb microsphere technology. Schizophr. Res. 60, 314 (2010).
86. Thyssen A, Rusch S, Herben V, Quiroz J, Mannaert E. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J. Clin. Pharmacol. 50(9), 1011-1021 (2010).
87. Heykants J, Huang ML, Mannens G et al. The pharmacokinetics of risperidone in humans: a summary. J. Clin. Psychiatry 55(Suppl.), 13-17 (1994).
88. Berecz R, Dorado P, de la RA, Caceres MC, Degrell I, LLerena A. The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. Curr. Drug Targets 5, 573-579 (2004).
89. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical signifcance: Part I. Clin. Pharmacokinet. 48, 689-723 (2009).
90. Package insert. Risperdal (risperidone): US prescribing information. (2010). Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Titusville, NJ, USA.
91. Elliott HL, Sumner DJ, McLean K, Reid JL. Effect of age on the responsiveness of vascular α-adrenoceptors in man. J. Cardiovasc. Pharmacol. 4, 388-392 (1982).
92. Andros E, Detmar-Hanna D, Suteparuk S, Gal J, Gerber JG. The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Eur. J. Clin. Pharmacol. 50, 41-46 (1996).
93. Volkow ND, Wang GJ, Fowler JS et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann. Neurol. 44, 143-147 (1998).
94. Volkow ND, Gur RC, Wang GJ et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am. J. Psychiatry 155, 344-349 (1998).
95. 11C-raclopride. Arch. Neurol. 50, 474-480 (1993).
96. Woolcott JC, Richardson KJ, Wiens MO et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch. Intern. Med. 169, 1952-1960 (2009).
97. Caligiuri MP, Lacro JP, Jeste DV. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J. Clin. Psychopharmacol. 19, 322-328 (1999).
98. Hoffman WF, Labs SM, Casey DE. Neuroleptic-induced parkinsonism in older schizophrenics. Biol. Psychiatry 22, 427-439 (1987).
99. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294, 1934-1943 (2005).
100. Spina E, Avenoso A, Scordo MG et al. Inhibition of risperidone metabolism by fuoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J. Clin. Psychopharmacol. 22, 419-423 (2002).
101. Csernansky JG, Newcomer JW, Jackson K et al. Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics. Psychopharmacology (Berl.) 116, 291-296 (1994).
102. Spina E, Avenoso A, Facciola G et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther. Drug Monit. 22, 481-485 (2000).
103. Bork JA, Rogers T, Wedlund PJ, de Lean J. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J. Clin. Psychiatry 60, 469-476 (1999).
104. Dunner DL. Drug interactions of lithium and other antimanic/mood- stabilizing medications. J. Clin. Psychiatry 64(Suppl. 5), 38-43 (2003).
105. Spina E, D'Arrigo C, Migliardi G et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther. Drug Monit. 28, 599-602 (2006).
106. Rosaria MM, Pacetti M, Cacciola M et al. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia 46, 771-774 (2005).
107. Savas HA, Yumru M, Ozen ME. Use of long-acting risperidone in the treatment of bipolar patients. J. Clin. Psychopharmacol. 26, 530-531 (2006).
108. Bech P, Bolwig TG, Dein E, Jacobsen O, Gram LF. Quantitative rating of manic states. Correlation between clinical assessment and Biegel's Objective Rating Scale. Acta Psychiatr. Scand. 52, 1-6 (1975).
109. Han C, Lee MS, Pae CU, Ko YH, Patkar AA, Jung IK. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 1219-1223 (2007).
110. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133, 429-435 (1978).
111. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol. Rep. 10, 799-812 (1962).
112. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56-62 (1960).
113. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ No ADM 76-338). National Institute of Mental Health, MD, USA, 218-222 (1976).
114. Braunig P, Sacchetti E, Medori R. Risperidone long-acting injectable for maintenance therapy in bipolar disorder: an open-label pilot study. Int. J. Psychiatry Clin. Pract. 12, 74-77 (2008).
115. Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. Effcacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int. Clin. Psychopharmacol. 20, 121-130 (2005).
116. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261-276 (1987).
117. Startup M, Jackson MC, Bendix S. The concurrent validity of the Global Assessment of Functioning (GAF). Br. J. Clin. Psychol. 41, 417-422 (2002).
118. Malempati RN, Bond DJ, Yatham LN. Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. Int. Clin. Psychopharmacol. 23, 88-94 (2008).
119. Vieta E, Nieto E, Autet A et al. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J. Biol. Psychiatry 9, 219-224 (2008).
120. Benabarre A, Castro P, Sanchez-Moreno J et al. [Effcacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder]. Actas Esp. Psiquiatr. 37, 143-147 (2009).
121. Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr. Scand. Suppl., 50-56 (2007).
122. Macfadden W, Alphs L, Haskins JT et al A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 11, 827-839 (2009).
123. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol. Psychiatry 68, 156-162 (2010).
124. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389 (1979).
125. Hamilton M. Hamilton Anxiety Scale. In: ECDEU Assessment Manual for Psychopharmacology. Guy W (Ed.). Department of Health, Education and Welfare, MD, USA, 193-198 (1976).
126. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16, 199-208 (1990).
127. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modifcation of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 73, 159-171 (1997).
128. Peselow ED, Dunner DL, Fieve RR, Lautin A. Lithium carbonate and weight gain. J. Affect. Disord. 2, 303-310 (1980).
129. Ness-Abramof R, Apovian CM. Drug-induced weight gain. Timely Top. Med. Cardiovasc. Dis. 9, E31 (2005).
130. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 24, 969-978 (2001).
131. Gartlehner G, Thieda P, Hansen RA et al Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf. 31, 851-865 (2008).
132. Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J. Nerv. Ment. Dis. 173, 353-357 (1985).
133. Barnes TR. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154, 672-676 (1989).
134. Simpson GM, Angus J W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 212, 11-19 (1970).
135. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64, 2291-2314 (2004).
136. Meltzer HY, Bobo WV, Nuamah IF et al. Effcacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J. Clin. Psychiatry 69, 817-829 (2008).
137. Lindenmayer JP, Czobor P, Alphs L et al. The InterSePT scale for suicidal thinking reliability and validity. Schizophr. Res. 63, 161-170 (2003).
138. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int. J. Neuropsychopharmacol. 11, 999-1029 (2008).
139. Berk L, Hallam KT, Colom F et al. Enhancing medication adherence in patients with bipolar disorder. Hum. Psychopharmacol. 25, 1-16 (2010).
140. Keck PE Jr, McElroy SL, Strakowski SM et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am. J. Psychiatry 155, 646-652 (1998).
141. Strakowski SM, Keck PE Jr, McElroy SL et al. Twelve-month outcome after a frst hospitalization for affective psychosis. Arch. Gen. Psychiatry 55, 49-55 (1998).
142. Velligan DI, Wang M, Diamond P et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr. Serv. 58, 1187-1192 (2007).
143. Byerly M, Fisher R, Whatley K et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 133, 129-133 (2005).
144. Calabrese JR, Vieta E, El-Mallakh R et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol. Psychiatry 56, 957-963 (2004).
145. Nierenberg AA, Ostacher MJ, Calabrese JR et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am. J. Psychiatry 163, 210-216 (2006).
146. Ghaemi SN, Sachs GS. Long-term risperidone treatment in bipolar disorder: 6-month follow up. Int. Clin. Psychopharmacol. 12, 333-338 (1997).
147. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J. Affect. Disord. 50, 143-151 (1998).
148. Vieta E, Gasto C, Otero A, Nieto E, Vallejo J. Differential features between bipolar I and bipolar II disorder. Compr. Psychiatry 38, 98-101 (1997).
149. Benazzi F. Bipolar II disorder: epidemiology, diagnosis and management. CNS Drugs 21, 727-740 (2007).
150. Grant BF, Stinson FS, Hasin DS et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 66, 1205-1215 (2005).
151. McElroy SL, Altshuler LL, Suppes T et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am. J. Psychiatry 158, 420-426 (2001).
152. Feinman JA, Dunner DL. The effect of alcohol and substance abuse on the course of bipolar affective disorder. J. Affect. Disord. 37, 43-49 (1996).
153. Mazza M, Mandelli L, Di Nicola M et al. Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. J. Affect. Disord. 115, 27-35 (2009).
154. Dalton EJ, Cate-Carter TD, Mundo E, Parikh SV, Kennedy JL. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord. 5, 58-61 (2003).
155. Turkington A, Mulholland CC, Rushe TM et al. Impact of persistent substance misuse on 1-year outcome in frst-episode psychosis. Br. J. Psychiatry 195, 242-248 (2009).
156. Perlis RH, Ostacher MJ, Miklowitz DJ et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J. Clin. Psychiatry 71, 296-303 (2010).
157. Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 8, 232-241 (2006).
158. Manwani SG, Szilagyi KA, Zablotsky B, Hennen J, Griffn ML, Weiss RD. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. J. Clin. Psychiatry 68, 1172-1176 (2007).
159. Lee S, Tsang A, Kessler RC et al. Rapid-cycling bipolar disorder: cross-national community study. Br. J. Psychiatry 196, 217-225 (2010).
160. Nierenberg AA, Akiskal HS, Angst J et al. Bipolar disorder with frequent mood episodes in the national comorbidity survey replication (NCS-R). Mol. Psychiatry DOI: 10.1038/mp.2009.61 (2009) (Epub ahead of print).
161. Sharma R, Markar HR. Mortality in affective disorder. J. Affect. Disord. 31, 91-96 (1994).
162. Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: why the excess cardiovascular risk in bipolar disorder? Curr. Psychiatry Rep. 11, 475-480 (2009).
163. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J. Clin. Psychiatry 67, e16 (2006).
164. Birkenaes AB, Opjordsmoen S, Brunborg C et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J. Clin. Psychiatry 68, 917-923 (2007).
165. Glazer WM. The depot paradox. Behav. Healthc. 27, 44-46 (2007).
166. Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J. Clin. Psychiatry 70, 196-200 (2009).
167. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J. Clin. Psychiatry 67, 1948-1953 (2006).
168. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 175, 58-62 (2010).
169. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol. Med. 33, 83-89 (2003).